Unibest
← Back to patent-cliff list

Platelet membrane coated resiquimod nanoparticles (Cello Therapeutics)

Tier C — Watch / trade

Platelet membrane coated resiquimod nanoparticles (Cello Therapeutics)

Cello Therapeutics Inc
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type

Targets:TLR8, TLR7

Indications (approved):Solid tumour

Regional status

US
-
EU
-
China
-
Japan
-

Synthetic routes & intermediates

Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.

Frequently asked questions

What are the approved indications of Platelet membrane coated resiquimod nanoparticles (Cello Therapeutics)?

Approved indications include: Solid tumour.

When does the Platelet membrane coated resiquimod nanoparticles (Cello Therapeutics) patent expire?

No public expiry year is available for Platelet membrane coated resiquimod nanoparticles (Cello Therapeutics) yet; this page updates once verified.

How do I get a quote for Platelet membrane coated resiquimod nanoparticles (Cello Therapeutics) intermediates?

Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.

Source: cross-verified data (structured fields only) · 2026-09-29